Search

You searched for "therapeutics"

371 results found
Ophthalmologica journal cover image.

Changes in ocular biomarkers in Vogt-Koyanagi-Harada disease after pulse steroid therapy

2 October 2025 | | EYE - Vitreo-Retinal
This retrospective study aimed to evaluate the early and chronological changes in ocular biomarkers in patients of Vogt Koyanagi Harada (VKH) disease who received pulse steroid therapy. It further aimed to identify which biomarkers correlated with the best corrected visual...

RANZCO Congress 2025

14 November 2025 -17 November 2025
The Royal Australian and New Zealand College of Ophthalmologists Annual Congress 2025

Learnings and trends in the management of open-angle and angle-closure glaucoma

1 August 2017 | | EYE - Glaucoma
To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Birdshot retinochoroiditis

1 June 2022 | | EYE - Vitreo-Retinal, EYE - General
Birdshot retinochoroiditis (BRC) is a chronic, sight-threatening uveitis, most commonly affecting caucasian individuals in their fourth to sixth decades [1]. The disease is associated with HLA-29 and is characterised by progressive inflammation at the level of retina and choroid, with...

Pegcetacoplan: A breakthrough treatment for dry age-related macular degeneration?

12 February 2025 | | EYE - Pathology, EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is a degenerative condition affecting the macula, the part of the retina responsible for central vision. It is characterised by the presence of drusen and retinal pigment epithelium (RPE) abnormalities in the absence of other macular...

The role of aspirin in the treatment of NAION: Benefits and controversies

4 December 2024 | | EYE - Neuro-ophthalmology
Non-arteritic anterior ischaemic optic neuropathy (NAION) is the most common acute optic neuropathy in individuals over 50 with estimated prevalence of 2–10 per 100,000 people, characterised by sudden, unilateral vision loss due to ischaemic injury to the optic nerve head....

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

1 August 2018 | | EYE - General
Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...

Eye research: where next?

1 December 2017
Eye research in the UK is underfunded relative to other areas of medical research and general awareness of sight loss and its prevention remains poor, messages that were reinforced in presentations and discussions during a recent research summit meeting in...

An update on idiopathic intracranial hypertension

1 August 2017 | | EYE - Neuro-ophthalmology
The incidence of Idiopathic intracranial hypertension (IIH) is increasing, likely in line with the worldwide epidemic of obesity. To date, there have been revisions in the terminology used and diagnostic criteria for IIH; these recognise the need to exclude secondary...

Conservative management of concomitant strabismus

1 October 2019 | | EYE - General
The aim of management for all patients with strabismus should centre around four goals: to prevent amblyopia, to alleviate symptoms, to restore binocular single vision (BSV) and to improve ocular alignment. The conservative management options available for strabismus include observation,...

My top five: Innovative approaches to dry AMD

2 February 2024 | | EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...

My Top Five: Innovative approaches to dry AMD

2 February 2024 | | EYE - General
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...